Arteriovenous Access Type and Risk of Mortality, Hospitalization, and Sepsis Among Elderly Hemodialysis Patients: A Target Trial Emulation Approach

Am J Kidney Dis. 2022 Jan;79(1):69-78. doi: 10.1053/j.ajkd.2021.03.030. Epub 2021 Jun 9.

Abstract

Rationale & objective: Evidence is mixed regarding the optimal choice of the first permanent vascular access for elderly patients receiving hemodialysis (HD). Lacking data from randomized controlled trials, we used a target trial emulation approach to compare arteriovenous fistula (AVF) versus arteriovenous graft (AVG) creation among elderly patients receiving HD.

Study design: Retrospective cohort study.

Setting & participants: Elderly patients included in the US Renal Data System who initiated HD with a catheter and had an AVF or AVG created within 6 months of starting HD.

Exposure: Creation of an AVF versus an AVG as the incident arteriovenous access.

Outcomes: All-cause mortality, all-cause and cause-specific hospitalization, and sepsis.

Analytical approach: Target trial emulation approach, high-dimensional propensity score and inverse probability of treatment weighting, and instrumental variable analysis using the proclivity of the operating physician to create a fistula as the instrumental variable.

Results: A total of 19,867 patients were included, with 80.1% receiving an AVF and 19.9% an AVG. In unweighted analysis, AVF creation was associated with significantly lower risks of mortality and hospitalization, especially within 6 months after vascular access creation. In inverse probability of treatment weighting analysis, AVF creation was associated with lower incidences of mortality and hospitalization within 6 months after creation (hazard ratios of 0.82 [95% CI, 0.75-0.91] and 0.82 [95% CI, 0.78-0.87] for mortality and all-cause hospitalization, respectively), but not between 6 months and 3 years after access creation. No association between AVF creation and mortality, sepsis, or all-cause, cardiovascular disease-related, or infection-related hospitalization was found in instrumental variable analyses. However, AVF creation was associated with a lower risk of access-related hospitalization not due to infection.

Limitations: Potential for unmeasured confounding, analyses limited to elderly patients, and absence of data on actual access use during follow-up.

Conclusions: Using observational data to emulate a target randomized controlled trial, the type of initial arteriovenous access created was not associated with the risks of mortality, sepsis, or all-cause, cardiovascular disease-related, or infection-related hospitalization among elderly patients who initiated HD with a catheter.

Keywords: Arteriovenous access; HD access; arteriovenous fistula (AVF); arteriovenous graft (AVG); elderly; end-stage renal disease (ESRD); hemodialysis (HD); hospitalization; mortality; sepsis; target trial; vascular access.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Arteriovenous Shunt, Surgical* / adverse effects
  • Hospitalization
  • Humans
  • Kidney Failure, Chronic* / therapy
  • Renal Dialysis / adverse effects
  • Retrospective Studies
  • Sepsis* / therapy